Home / Health / Trump's US Policy Skyrockets Scotland's Obesity Drug Costs
Trump's US Policy Skyrockets Scotland's Obesity Drug Costs
25 Jan
Summary
- Scotland's NHS now spends nearly £3 million monthly on weight-loss injections.
- US policy change significantly increased the cost of Mounjaro in Scotland.
- Weight-loss drugs offer substantial health benefits beyond weight reduction.
The cost of Scotland's battle against obesity has reached unprecedented levels, with the nation's NHS now spending nearly £3 million monthly on weight-loss injections.
This dramatic increase is partly attributed to a policy shift initiated by former US President Donald Trump. His directive for American pharmaceutical firms to prioritize lower prices for US citizens led Eli Lilly, the manufacturer of Mounjaro, to raise its UK prices. Consequently, the average cost per Mounjaro injection for the Scottish NHS more than doubled overnight, from £99 to £215.
Demand for these injections, including Mounjaro, Ozempic, and Wegovy, has surged since they became available on prescription. In September, nearly 20,000 injections were prescribed, a significant rise from 8,207 in January, which cost the NHS £692,000. By September, the monthly cost had escalated to £2.71 million.
Despite the rising costs, medical experts emphasize the crucial role of these weight-loss injections in combating obesity and associated health conditions. They highlight that these drugs not only aid in weight loss but also substantially reduce the risk of serious health issues such as kidney disease, heart failure, heart attacks, and sleep apnoea.
